MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA
Recommended Citation
Nguyen D, Besse B, Cho BC, Lee S, Lee KH, Lu S, Cheng Y, Yao Y, Girard N, Lin C, Felip E, Aguilar A, Charoentum C, Cruz FJ, Majem M, Lim CS, Akamatsu H, Hayashi H, Yang JC, Kowalyszyn R, Tiscoski K, Franke F, Ponomarenko D, Arslan C, Forster M, Urban D, Misch D, Delmonte A, Montes LV, Gadgeel SM, Cruz-Correa M, Peguero J, Rousey S. MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA. J Thorac Oncol 2024; 19(10):S103-S104.
Document Type
Conference Proceeding
Publication Date
10-1-2024
Publication Title
J Thorac Oncol
Abstract
Introduction: Amivantamab is an epidermal growth factor receptor (EGFR)-MET bispecific antibody with immune cell-directing activity. Lazertinib is a highly selective, CNS-penetrant, EGFR tyrosine kinase inhibitor (EGFR-TKI). In MARIPOSA (NCT04487080), amivantamab plus lazertinib (amivantamab-lazertinib) significantly prolonged progression-free survival (PFS) vs osimertinib (hazard ratio [HR], 0.70; P<0.001) in patients with treatment-naïve, EGFR-mutant advanced non-small cell lung cancer (NSCLC; Cho Ann Oncol 2023;34:S1306;LBA14). We evaluated time to symptomatic progression (TTSP) and patient-reported outcomes (PROs) from MARIPOSA. Methods: Analyses included the 429 patients randomized to receive amivantamab-lazertinib and the 429 to osimertinib. TTSP was defined as time from randomization to onset of new/worsening lung cancer symptoms requiring change in anticancer therapy, another clinical intervention, or death, whichever occurred first. PROs were measured using EORTC-QLQ-C30 and NSCLC-SAQ; all P-values are nominal. The threshold for a meaningful improvement was a 10-point increase on EORTC-QLQ-C30 functioning scales. Results: At a median follow-up of 22.0 months, amivantamab-lazertinib demonstrated a significant improvement in TTSP versus osimertinib (HR, 0.72; 95% confidence interval, 0.57-0.91; P=0.005). As median treatment duration was 18.5 months for amivantamab-lazertinib versus 18 months for osimertinib, PROs at 18 months are reported to evaluate the long term impact of treatment on quality of life. Based on the EORTC-QLQ-C30 functioning scales at 18 months, the percentage of randomized patients on treatment with improved or stable functioning relative to baseline in the amivantamab-lazertinib versus osimertinib arms was significantly higher for emotional functioning (38% versus 31%; P<0.05) and cognitive functioning (38% versus 31%; P<0.05). For other functioning scales, no statistically significant differences between amivantamab-lazertinib and osimertinib were observed. Functioning was maintained over time in both treatment arms as most changes over time were less than the defined threshold for clinically meaningful differences. At 18 months, no statistical differences were observed between the amivantamab-lazertinib and osimertinib arms for the absence of key symptoms from the EORTC-QLQ-C30 including dyspnea (34% versus 31%), pain (27% versus 26%), and fatigue (15% versus 16%). There were no significant differences in symptoms between arms based on the NSCLC-SAQ (Figure). Conclusions: For patients with treatment-naïve, EGFR-mutant advanced NSCLC, amivantamab-lazertinib significantly delayed symptomatic progression versus osimertinib indicating greater control of disease and related symptoms, while maintaining functioning as observed by PRO scales. PROs were comparable across treatment arms at the 18-month landmark, and treatment did not lead to meaningful decrements in patient quality of life. [Formula presented] Keywords: Amivantamab, EGFR TKI, NSCLC
Volume
19
Issue
10
First Page
S103
Last Page
S104
